Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
VALN
VALN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VALN News
Valneva to Participate in World Vaccine Congress 2026
4d ago
Newsfilter
Biotech Landscape Update: Regulatory Approvals and Mergers
3d ago
NASDAQ.COM
Valneva's Vaccine Trial Fails to Meet Primary Endpoint
6d ago
Globenewswire
Valneva's Lyme Disease Vaccine Candidate Shows Over 70% Efficacy
Mar 23 2026
NASDAQ.COM
Experimental Lyme Disease Vaccine Shows Over 70% Efficacy
Mar 23 2026
Yahoo Finance
Pfizer and Valneva Report Phase 3 Results for Lyme Disease Vaccine
Mar 23 2026
seekingalpha
Pfizer and Valneva Report Phase 3 Vaccine Trial Results
Mar 23 2026
NASDAQ.COM
Pfizer's Vaccine Candidate PF-07307405 Shows Over 70% Efficacy
Mar 23 2026
Newsfilter
PFIZER AND VALNEVA REPORT STRONG EFFICACY OF LYME DISEASE VACCINE CANDIDATE IN PHASE 3 VALOR TRIAL
Mar 23 2026
moomoo
Valneva SE Reports 2024 Earnings Highlights
Mar 18 2026
Yahoo Finance
Elaris FlexCo Secures Exclusive Vaccine Technology Rights from Valneva
Mar 18 2026
seekingalpha
Elaris Secures Exclusive License from Valneva for CDI Vaccine Technology
Mar 18 2026
PRnewswire
Elaris Secures Exclusive License from Valneva for CDI Vaccine Technology
Mar 18 2026
Newsfilter
Valneva SE Reports 2025 Financial Results and Strategic Outlook
Mar 18 2026
NASDAQ.COM
Valneva SE Reports Wider Net Loss for Fiscal 2025
Mar 18 2026
NASDAQ.COM
Valneva Reports 3% Revenue Growth to €174.7M for FY 2025
Mar 18 2026
seekingalpha
Show More News
